PBAC's latest decision on Nemolizumab: Recommended with restriction (2025). Considered for Treatment of chronic severe atopic dermatitis affecting the whole body, face, and/or hands in patients aged 12 years or older who are inadequately controlled on topical therapies.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2025
Submissions
1
2025 → 2025
Eligible population
Patients aged 12 years or older with chronic severe atopic dermatitis affecting the whole body or face and/or hands (EASI ≥20, PGA ≥4 on 5-point scale despite daily topical therapy for ≥28 days) who are inadequately controlled on topical therapies.
Therapy area
Dermatology
Line of therapy
Later-line
Evidence base
Indirect treatment comparison (ITC)
Primary endpoint
EASI-75 and IGA 0/1 at Week 16
Comparator
dupilumab
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis (CMA) employed; no ICER calculated by design.